Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Esneux – page 87

1 367 clinical trials in Esneux, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Esneux at a glance
1 367
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 367 trials in Esneux

Open in trial search

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer Consumer Care AG

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Plasma cell myeloma

Not recruiting

Study on Talquetamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Talquetamab
  • Sponsor:Janssen Cilag International

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Bladder cancer

Not recruiting

Study on the Effectiveness and Safety of Durvalumab with Gemcitabine and Cisplatin for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Breast neoplasm

Not recruiting

Study Comparing Abemaciclib and Fulvestrant with Placebo and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer After Previous Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Gastric cancer

Not recruiting

Study of ALX148 with Trastuzumab, Ramucirumab, and Paclitaxel for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Evorpacept
  • Sponsor:Alx Oncology Holdings Inc.

Study of Tobemstomig with Platinum-Based Chemotherapy vs Pembrolizumab with Platinum-Based Chemotherapy for Untreated Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Esneux

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) optimization in patients with chronic usage patterns. This study explores effective deprescribing strategies for individuals without clear long-term PPI indications.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Therapy Alternatives

The investigation compares on-demand PPI use and alginate formulation replacement against traditional gradual dose reduction, aiming to establish more effective treatment protocols for gastrointestinal conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.